Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dejongh

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Drug Metabolism Reviews|August 10, 2001
The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modelingB Ploeger, T Mensinga, A Sips, et al.
Toxicology and Applied Pharmacology|January 6, 2001
A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acidB Ploeger, T Mensinga, A Sips, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 27, 2010
Neurite degeneration in differentiated human neuroblastoma cellsM Nordin-Andersson, A Forsby, N Heldring, et al.
Chemosphere|March 30, 2000
Biotransformation rates of Ugilec 141 (tetrachlorobenzyltoluenes) in rat and trout microsomesH J Kramer, M van den Berg, R J Delang, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 27, 2010
An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS ProjectJ Dejongh, A Forsby, J B Houston, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2004
Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonistsM P Schaddelee, D Groenendaal, J DeJongh, et al.
Clinical Pharmacology and Therapeutics|August 10, 2007
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patientsM Y M Peeters, L J Bras, J DeJongh, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Drug Metabolism Reviews|August 10, 2001
The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modelingB Ploeger, T Mensinga, A Sips, et al.
Toxicology and Applied Pharmacology|January 6, 2001
A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acidB Ploeger, T Mensinga, A Sips, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 27, 2010
Neurite degeneration in differentiated human neuroblastoma cellsM Nordin-Andersson, A Forsby, N Heldring, et al.
Chemosphere|March 30, 2000
Biotransformation rates of Ugilec 141 (tetrachlorobenzyltoluenes) in rat and trout microsomesH J Kramer, M van den Berg, R J Delang, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 27, 2010
An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS ProjectJ Dejongh, A Forsby, J B Houston, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2004
Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonistsM P Schaddelee, D Groenendaal, J DeJongh, et al.
Clinical Pharmacology and Therapeutics|August 10, 2007
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patientsM Y M Peeters, L J Bras, J DeJongh, et al.
Pageof 2